May 3rd, 2018, Vancouver, British Columbia - PRESS RELEASE: PreveCeutical Medical Inc. has announced the grant of two additional permits by the Australian Government, Department of Health, for the importation of a second shipment of cannabis plant materials into Australia for research purposes and the shipment of dried cannabis materials pursuant to the permits. The permits, which were granted to the Pharmacy Australia Centre of Excellence (PACE) at the University of Queensland (UQ), allow PACE to import shipments of cannabis material for research purposes. PreveCeutical’s Canadian licensed producer partner has also received the required Canadian permits to export their medical cannabis materials to PACE.
The cannabis materials are used for PreveCeutical’s soluble gel (Sol-gel) drug delivery research program, for testing an array of cannabis strains for the development and commercialization of cannabinoid-based Sol-gels. The Program is led by PreveCeutical’s Chief Research Officer, Dr. Harendra Parekh and conducted by PreveCeutical’s research partner, the University of Queensland, and aims to develop a technology that will increase the bioavailability of drugs by using a nose-to-brain delivery system. By applying Sol-gel technology to cannabis, PreveCeutical intends to develop therapies for relief from a range of symptoms, including pain, inflammation, seizures and neurological disorders. The advantages of Sol-gels over conventional liquid nasal sprays include longer therapeutic effects, reduced dosage requirements, and reduced negative side effects, such as irritation.
